tert-butyl 3-hydroxy-2,4-dimethylazetidine-1-carboxylate

Catalog No.: 
ACJGXH764
CAS No.: 
2940950-42-3
Molecular Formula: 
C10H19NO3
Molecular Weight: 
201.27
tert-butyl 3-hydroxy-2,4-dimethylazetidine-1-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg95%$521.00In stockInquiry
100mg95%$831.00In stockInquiry
250mg95%$1329.00In stockInquiry
500mg95%$1994.00In stockInquiry
1g95%$3046.00In stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-butyl 3-hydroxy-2,4-dimethylazetidine-1-carboxylate
IUPAC Nametert-butyl 3-hydroxy-2,4-dimethylazetidine-1-carboxylate
MDL No.MFCD35151346
Molecular FormulaC10H19NO3
Molecular Weight201.27
SMILESO=C(N1C(C)C(O)C1C)OC(C)(C)C
InChI KeyUSARIBQWBBTUMO-UHFFFAOYSA-N
Synonymtert-butyl 3-hydroxy-2,4-dimethyl-azetidine-1-carboxylate;1-Azetidinecarboxylic acid, 3-hydroxy-2,4-dimethyl-, 1,1-dimethylethyl ester
CAS No.2940950-42-3

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACJGXH764 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACJGXH764 route product structure diagram
    ACJGXH7642940950-42-3In Stock
Inquiry

2. ACJGXH764 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACJGXH764 route product structure diagram
    ACJGXH7642940950-42-3In Stock
Inquiry

3. ACJGXH764 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACJGXH764 route product structure diagram
    ACJGXH7642940950-42-3In Stock
Inquiry

Comments (0)